CompaniesMyovant Sciences

Myovant Sciences

defunct

About

Defunct Company

Areas of Focus

Categories

Terminally Acquired

Clinical Trials (15)

Total Trials

15

As Lead Sponsor

11

As Collaborator

4

Total Enrollment

5,651

By Phase

PHASE2: 2PHASE4: 1NA: 1PHASE1: 2PHASE3: 8

By Status

COMPLETED: 12RECRUITING: 2WITHDRAWN: 1

Clinical Trials Pipeline15 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Today

Hover over trial bars to see details

Recent Trials

NCT06330805Collaborator

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

PHASE2Recruiting

70 participants

Started: Aug 12, 2024 · Completed: Dec 31, 2027

NCT05765500Collaborator

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

PHASE2Recruiting

110 participants

Started: Feb 12, 2024 · Completed: Jan 1, 2028

NCT05538689Collaborator

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

PHASE4Withdrawn

Started: Nov 20, 2022 · Completed: Oct 24, 2024

NCT05324098Collaborator

Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy

47 participants

Started: Mar 8, 2022 · Completed: Jul 31, 2023

NCT04714554Lead Sponsor

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

PHASE1Completed

43 participants

Started: Jan 6, 2021 · Completed: Mar 29, 2021

View all 15 trials →

Funding History (20)

8-K

Mar 10, 2023

8-K

Mar 1, 2023

DEFA14A

Feb 16, 2023

DEFA14A

Feb 2, 2023

8-K

Jan 26, 2023

DEFM14A

Jan 23, 2023

8-K

Oct 26, 2022

DEFA14A

Oct 25, 2022

DEFA14A

Oct 24, 2022

8-K

Oct 24, 2022